Work

BHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of Migraine (P7-12.009)

Year: 2025

Type: article

Study design: Study Protocol

Source: Neurology

DOI: 10.1212/wnl.0000000000211319

Authors: Beth Emerson, Anne Pieters, Beth Morris, Andrew Lucas, Volkan Granit, Christopher Jensen, Joris Vriens, Thomas Voets, Irfan Qureshi, Vladimir Coric, Richard Lipton

Institutions: Biohaven Pharmaceuticals (United States), KU Leuven, VIB-KU Leuven Center for Brain & Disease Research, Albert Einstein College of Medicine

Language: English

Topic: Migraine and Headache Studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409223056

FWCI: 1.907

Cites:

Cited by: 3

Related to: 10